Deubiquitinating enzymes (DUBs) are associated with numerous cellular signalling pathways and are implicated in the pathology of diseases such as cancer and neurological disorders. Current DUB-targeted inhibitors have limited potencies and specificities. In this project, I used a combination of biophysical, biochemical and structure-based drug discovery approaches to investigate the mechanism of action of competitive and allosteric DUB inhibitors.

Anu is currently a QA Associate at The Janssen Pharmaceutical Companies of Johnson & Johnson.